No 03 2017

The company has announced confidential submission of draft registration statement to the SEC to allow for a potential listing of ADSs in the United States.

The FDA has granted Premarket Approval (PMA) for RefluxStop, the company’s implant-based treatment for gastroesophageal reflux disease (GERD).

Swedish biotech company Akiram Therapeutics has signed an agreement with ITM Isotope Technologies Munich to supply non-carrier-added lutetium-177 for the clinical development of AKIR001.

Eyedentity, a company in the Karolinska Institutet Innovation Incubator, has closed an oversubscribed investment round led by Norrsken Launcher.

Pixelgen Technologies has closed an oversubscribed USD 15.5 million Series B financing to accelerate global commercialization of its Proxiome Kit and expand the company’s presence in key markets.

Merck and Moderna have reported positive topline results from the Phase 3 INTerpath-001 trial of intismeran autogene in combination with Keytruda in patients with completely resected, high-risk melanoma.

The company reported a 16% increase in revenue at constant exchange rates in the first six months of 2026, driven mainly by continued growth in Vyepti and Rexulti.